Acridine orange is an effective anti-cancer drug that affects mitochondrial function in osteosarcoma cells

Current Pharmaceutical Design

Volumn 21, Issue 28, 2015, Pages 4088-4094

  Fotia, Caterina ^a   Avnet, Sofia ^a   Kusuzaki, Katsuyuki ^b   Roncuzzi, Laura ^a   Baldini, Nicola ^a,c  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b Kyoto Kujo Hospital   (Japan)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acridine orange; Lysosomal acidity; Mitochondria; Osteosarcoma

Indexed keywords

ACRIDINE ORANGE; ADENOSINE TRIPHOSPHATE; DOXORUBICIN; PROCASPASE 3; UBIQUINOL CYTOCHROME C REDUCTASE; ANTINEOPLASTIC AGENT;

ACIDITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL PH; CELL VACUOLE; CELL VIABILITY; CELLS BY BODY ANATOMY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; LYSOSOME; MITOCHONDRIAL TOXICITY; MITOCHONDRION; OSTEOSARCOMA CELL; OSTEOSARCOMA CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY CHAIN; WESTERN BLOTTING; BONE NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ACRIDINE ORANGE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LYSOSOMES; MITOCHONDRIA; OSTEOSARCOMA;

EID: 84947751982     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150918144953     Document Type: Article

References (33)

1. Millot C, Millot JM, Morjani H, et al. Characterization of acidic vesicles in multidrug-resistant and sensitive cancer cells by acridine orange staining and confocal microspectrofluorometry. J Histochem Cytochem 1997; 45: 1255-64.
2. Kusuzaki K, Suginoshita T, Minami G, et al. Fluorovisualization effect of acridine orange on mouse osteosarcoma. Anticancer Res 2000; 20: 3019-24.
3. Avnet S, Di Pompo G, Lemma S, et al. V-ATPase is a candidate therapeutic target for Ewing sarcoma. Biochim Biophys Acta 2013; 1832: 1105-16.
4. Perut F, Avnet S, Fotia C, et al. V-ATPase as an effective therapeutic target for sarcomas. Exp Cell Res 2014; 320: 21-32.
5. Ferrari S, Perut F, Fagioli F, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J Transl Med 2013; 11: 268.
6. Kusuzaki K, Hosogi S, Ashihara E, et al. Translational research of photodynamic therapy with acridine orange which targets cancer acidity. Curr Pharm Des 2012; 18: 1414-20.
7. Kusuzaki K, Murata H, Matsubara T, et al. Clinical trial of photodynamic therapy using acridine orange with/without low dose radiation as new limb salvage modality in musculoskeletal sarcomas. Anticancer Res 2005; 25: 1225-35.
8. Tatsuta M, Yamamura H, Yamamoto R, et al. Destruction of implanted gastric tumors in rats by acridine orange photoactivation with an argon laser. Eur J Cancer Clin Oncol 1984; 20: 543-52.
9. Prosser E, Cox D, O'Kennedy R, et al. Effects of coumarins, haematoporphyrins and acridine orange on the viability and growth of Landshutz ascites tumour cells, in the presence and absence of photoradiation. Cancer Lett 1990; 52: 71-77.
10. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/ osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000; 18: 4016-27.
11. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 2004-11.
12. He H, Ni J and Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett 2014; 7: 1352-62.
13. Gottesman MM and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
14. Kunjachan S, Rychlik B, Storm G, et al. Multidrug resistance: Physiological principles and nanomedical solutions. Adv Drug Deliv Rev 2013; 65: 1852-65.
15. Baldini N. Multidrug resistance--a multiplex phenomenon. Nat Med 1997; 3: 378-80.
16. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of Pglycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333: 1380-5.
17. Altan N, Chen Y, Schindler M et al. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 1998; 187: 1583-98.
18. Kusuzaki K, Takeshita H, Murata H, et al. Polyploidization induced by acridine orange in mouse osteosarcoma cells. Anticancer Res 2000; 20: 965-70.
19. Satonaka H, Kusuzaki K, Akeda K, et al. Acridine orange inhibits pulmonary metastasis of mouse osteosarcoma. Anticancer Res 2011; 31: 4163-68.
20. Nakamura T, Kusuzaki K, Matsubara T, et al. Determination of the LD50 of acridine orange via intravenous administration in mice in preparation for clinical application to cancer therapy. In Vivo 2014; 28: 523-7.
21. Roncuzzi L, Pancotti F, Baldini N. Involvement of HIF-1alpha activation in the doxorubicin resistance of human osteosarcoma cells. Oncol Rep 2014; 32: 389-94.
22. Petersen NH, Olsen OD, Groth-Pedersen L, et al. Transformationassociated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 2013; 24: 379-93.
23. Zelenin AV, Liapunova EA. Inhibition of protein synthesis by acridine orange. Nature 1964; 204: 45-46.
24. Goormaghtigh E, Huart P, Brasseur R, et al. Mechanism of inhibition of mitochondrial enzymatic complex I-III by adriamycin derivatives. Biochim Biophys Acta 1986; 861: 83-94.
25. Gohil VM, Hayes P, Matsuyama S, et al. Cardiolipin biosynthesis and mitochondrial respiratory chain function are interdependent. J Biol Chem 2004; 279: 42612-18.
26. Chavez E, Zazueta C, Garcia N, et al. Titration of cardiolipin by either 10-N-nonyl acridine orange or acridine orange sensitizes the adenine nucleotide carrier to permeability transition. J Bioenerg Biomembr 2008; 40: 77-84.
27. Poyry S, Cramariuc O, Postila PA, et al. Atomistic simulations indicate cardiolipin to have an integral role in the structure of the cytochrome bc1 complex. Biochim Biophys Acta 2013; 1827: 769- 78.
28. Petrosillo G, Ruggiero FM, Paradies G. Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. FASEB J 2003; 17: 2202-8.
29. Dong Y, Berners-Price SJ, Thorburn DR, et al. Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy. Biochem Pharmacol 1997; 53: 1673-82.
30. Boland ML, Chourasia AH, Macleod KF. Mitochondrial dysfunction in cancer. Front Oncol 2013; 3: 292.
31. Bannazadeh Amirkhiz M, Rashtchizadeh N, Nazemiyeh H, et al. Investigating apoptotic effects of methanolic extract of dorema glabrum seed on WEHI-164 cells. ISRN Pharmacol 2013; 2013: 949871.
32. Fernández Larrosa PN, Croci DO, Riva DA, et al. Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway. Retrovirology 2008; 5: 19.
33. Jung K, Reszka R. Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev 2001; 49: 87-105.